NASDAQ · TTRX
Turn Therapeutics Inc.
$10.72-$0.40 (-3.6%)
Turn Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.83% below the high.
Loading market information…
NASDAQ · IXHL · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Incannex Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 82.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Incannex Healthcare Limited’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.66. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Incannex Healthcare Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | May 15, 2025 | -$7.21+47.79% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q2 2025 | Feb 14, 2025 | -$9.91+24.92% vs estimate | $108.99K+8.99% vs estimate |
|---|
| Q4 2024 | Nov 14, 2024 | -$10.83-1,325.0% vs estimate | $74.00K-52.26% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.72-$0.40 (-3.6%)
Turn Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.83% below the high.
$7.09-$0.04 (-0.56%)
Agenus Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.23% below the high.
$3.65-$0.03 (-0.82%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.37% below the high.
$2.93-$0.02 (-0.68%)
SkyAI, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.71% below the high.
$1.94-$0.05 (-2.51%)
Seer, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.49% below the high.
$0.43+$0.02 (+5.03%)
Lucid Diagnostics Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.48% below the high.
$0.74-$0.01 (-1.28%)
Cognition Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
$1.43+$0.01 (+0.7%)
Zhengye Biotechnology Holding Limited’s quoted price sits in the lower half of its reported 52-week range, 82.15% below the high.
